Advances in fibromyalgia: Possible role for central neurochemicals

American Journal of the Medical Sciences

Volumn 315, Issue 6, 1998, Pages 377-384

  Russell, I Jon ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Allodynia; Fibromyalgia; Pathogenesis; Serotonin; Substance P

Indexed keywords

DYNORPHIN A; NERVE GROWTH FACTOR; NEUROTRANSMITTER; SEROTONIN; SUBSTANCE P;

ALLODYNIA; ANTINOCICEPTION; CHRONIC PAIN; CONFERENCE PAPER; FIBROMYALGIA; HUMAN; NEUROCHEMISTRY; NEUROPATHOLOGY; NOCICEPTION; NONHUMAN;

EID: 0031749023     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199806000-00006     Document Type: Conference Paper

References (67)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum. 1990;33:160-72.
2. Bonica JJ. Definitions and taxonomy of pain. In: Bonica JJ, Loeser JD, Chapman CR, Fordyce WE, eds. The Management of Pain. Vol. I. 2nd ed. Philadelphia: Lea & Febiger; 1990:18-27.
3. 2 laser stimulation in subjects with fibromyalgia syndrome. Pain. 1994;58:185-93.
4. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxy-genase inhibition. Science. 1992;257:1276-9.
5. Russell IJ. Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskeletal Pain. 1996;1:61-92.
6. Yunus MB, Kalyan-Raman UP, Masi AT, Aldag JC. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol. 1989;16:97-101.
7. Vaeroy H, Helle R, Force O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988;32:21-6.
8. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal levels of substance P in patients with fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593-1601.
9. Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in csf from fibromyalgia patients. J Musculoskeletal Pain. 1995;3(suppl1):4.
10. Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995;38:926-38.
11. Bradley LA, Alberts KR, Alarcon GS, Alexander MT, et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis Rheum. 1996;39(suppl9):S212.
12. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol. 1992;19:104-9.
13. Stratz T, Samborski W, Hrycaj P, Pap T, Mackiewicz S, Mennet P, Muller W. Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritis (in German). Med Klin. 1993;88:458-62.
14. Hrycaj P, Stratz T, Muller W. Platelet 3H-imipramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. J Rheumatol. 1993;20:1986-7.
15. Wolfe F, Russell IJ, Vipraio GA, Ross K, Anderson J. Serotonin levels, pain threshold, and FM. J Rheumatol. 1997;24:555-9.
16. Fischer H, Eich, Russell IJ. Neuropeptides in saliva. Semin Arthritis Rheum. 1997 (in press).
17. Tsigos C, Diemel LT, Tomlinson DR, Young RJ. Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clin Sci. 1993;84:305-11.
18. Simms RW, Goldenberg DL. Symptoms mimicking neurologic disorders in fibromyalgia syndrome. J Rheumatol. 1988;15:1271-3.
19. Mengshoel AM, Saugen E, Forre O, Vollestad NK. Muscle fatigue in early fibromyalgia. J Rheumatol. 1995;22:143-50.
20. Becquet D, Faudon M, Hery F. The role of serotonin release and autoreceptors in the dorsalis raphe nucleus in the control of serotonin release in the cat caudate nucleus. Neuroscience. 1990;39:639-47.
21. Sorkin LS, McAdoo DJ, Willis WD. Raphe magnus stimu- lation-induced antinociception in the cat is associated with release of amino acids as well as serotonin in the lumbar dorsal horn. Brain Res. 1993;618:95-108.
22. Larson AA, Igwe OJ, Seybold VS. Effects of lysergic acid diethylamide (LSD) and adjuvant-induced inflammation on desensitization to and metabolism of substance P in the mouse spinal cord. Pain. 1989;37:365-73.
23. Naranjo JR, Arnedo A, Molinero MT, Del Rio J. Involvement of spinal monoaminergic pathways in antinociception produced by substance P and neurotensin in rodents. Neuropharmacology. 1989;28:291-8.
24. Eide PK, Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Res. 1991;550:225-30.
25. Arvidsson U, Cullheim S, Ulfhake B, Luppi PH, Kitahama K, Jouvet M, Hokfelt T. Quantitative and qualitative aspects on the distribution of 5-HT and its coexistence with substance P and TRH in cat ventral medullary neurons (published erratum appears in J Chem Neuroanat. 1994;7:285-7). J Chem Neuroanat. 1994;7:3-12.
26. Walker PD, Schotland S, Hart RP, Jonakait GM. Tryptophan hydroxylase inhibition increases preprotachykinin mRNA in developing and adult medullary raphe nuclei. Brain Res Mol Brain Res. 1990;8:113-9.
27. Walker PD, Riley LA, Hart RP, Jonakait GM. Serotonin regulation of tachykinin biosynthesis in the rat neostriatum. Brain Res. 1991;546:33-9.
28. Murphy RM, Zemlan FP. Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacology (Berlin). 1987;93:118-21.
29. Sharma HS, Nyberg F, Olsson Y, Dey PK. Alteration of substance P after trauma to the spinal cord: an experimental study in the rat. Neurosci. 1990;38:205-12.
30. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system, serotonin and pain. Adv Neurol. 1982;33:51-7.
31. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K. Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol. 1989;19(suppl):158-63.
32. Russell IJ, Vipraio GA, Acworth I. Abnormalities in the central nervous system (CNS) metabolism of tryptophan (TRY) to 3-hydroxykynurenine (OHKY) in fibromyalgia syndrome (FS). Arthritis Rheum. 1993;36(suppl9):S222.
33. Russell IJ, Vipraio GA. Serotonin (5HT) in serum and platelets (PLT) from fibromyalgia patients (FS) and normal controls (NC). Arthritis Rheum. 1994;37(suppl):S214.
34. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-6.
35. Kang Y-K, Russell IJ, Vipraio GA, Acworth IN. Low urinary 5-hydroxyindole acetic acid in fibromyalgia syndrome: evidence in support of a serotonin-deficiency pathogenesis. Myalgia. 1998 (in press).
36. Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology. 1992;17:593-8.
37. Russell IJ, Vodjani A, Michalek JE, Vipraio GA, Lopez Y, MacKillip F. Circulating antibodies to serotonin in fibromyalgia syndrome, rheumatoid arthritis, osteoarthrosis, and healthy normal controls. J Musculoskeletal Pain. 1995;3(suppl1):143.
38. Baba H, Kaune GC, Ilyas AA, Pestronk A, Cornblath DR, Chaudhry V, et al. AntiGm1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy. J Neuroimmunol. 1989;25:143-50.
39. Vedder CI, Bennett RM. An analysis of antibodies to sero- tonin receptors in fibromyalgia. J Musculoskeletal Pain. 1995;3(suppl1):73.
40. Hornfeldt CS, Sun X, Larson AA. The NH2-terminus of substance P modulates NMDA-induced activity in the mouse spinal cord. J Neurosci. 1994;14:3364-9.
41. Hoheisel U, Mense S, Ratkai M. Effects of spinal cord superfusion with substance P on the excitability of rat dorsal horn neurons processing input from deep tissues. J Musculo-skeletal Pain. 1996;3(3):23-43.
42. Reynolds WJ, Chiu B, Inman RD. Plasma substance P levels in fibrositis. J Rheumatol. 1988;15:1802-3.
43. 1-7) in fibromyalgia syndrome (FS) cerebrospinal fluid (CSF). J Musculoskel Pain. 1995;3(suppl1):5.
44. Sjostrom S, Tamsen A, Hartvig P, Folkesson R, Terenius L. Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg. 1988;67:976-81.
45. Almay BG, Johansson F, von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain. 1988;33:3-9.
46. Guieu R, Tardy-Gervet MF, Giraud P, Boudouresque F. Met-enkephalin and substance P: comparison of CSF levels in patients with chronic pain based on a sampling procedure (in French). Revue Neurologique. 1993;149:398-401.
47. Nyberg F, Liu Z, Lind C, Thornwall M, Ordeberg G. Enhanced CSF levels of substance P in patients with painful arthrosis but not in patients with pain from herniated lumbar discs. J Musculoskeletal Pain. 1995;3(suppl1):2.
48. Mejia JA, Pernow J, von Holst H, Rudehill A, Lundberg JM. Effects of neuropeptide Y, calcitonin gene-related peptide, substance P, and capsaicin on cerebral arteries in man and animals. J Neurosurg. 1988;69:913-8.
49. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37:1583-92.
50. Long JB, Rigamonti DD, Oleshansky MA, Wingfield CP, Martinez-Arizala, A. Dynorphin A-induced rat spinal cord injury: evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury. J Pharmacol Exp Ther. 1994;269:358-66.
51. Vaeroy H, Nyberg F, Terenius L. No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7. Pain. 1991;46:139-43.
52. Johnson M, Hanson GR, Gibb JW, Adair J, Filloux F. Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, dynorphin A and substance P concentrations in rats. Brain Res Dev Brain Res. 1994;83:109-18.
53. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor (NGF) in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1997 (Submitted).
54. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience. 1992;49:693-8.
55. Otten U, Goedert M, Mayer M, Lembeck F. Requirement of nerve growth factor for the development of substance P containing neurones. Nature. 1980;287:158-9.
56. Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 1992;355:75-8.
57. Andreev NY, Dimitrieva AN, Koltzenburg M, McMohon SB. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain. 1995;63:109-16.
58. Tamatani M, Senba E, Tohyama M. Calcitonin gene-related peptide- and substance P-containing primary afferent fibers in the dorsal column of the rat. Brain Res. 1989;495:122-30.
59. Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L. Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene related peptide (CGRP). J Rheumatol. 1989;19(suppl):94-7.
60. Nyberg F, LeGreves P, Sundqvist C, Terenius L. Characterization of substance P(1-7) and (1-8) generating enzyme in human cerebrospinal fluid. Biochem Biophys Res Commun. 1984;125:244-50.
61. Skilling SR, Smullin DH, Larson AA. Differential effects of C- and N-terminal substance P metabolites on the release of amino acid neurotransmitters from the spinal cord: potential role in nociception. J Neurosci. 1990;10:1309-18.
62. Yukhananov RY, Larson AA. An N-terminal fragment of sub- stance P, substance P(1-7), down-regulates neurokinin-1 binding in the mouse spinal cord. Neuroscience. 1994;178:163-6.
63. Vanderah TW, Laughlin T, Lashbrook JM, Nichols ML, Wilcox GL, Ossipov MH, et al. Single intrathecal injections of dynorphin A or des-tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain. 1996;68:275-81.
64. Faden AI. Opioid and nonopioid mechanisms may contribute to dynorphin's pathophysiological actions in spinal cord injury. Ann Neurol. 1990;27:67-74.
65. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury: a controlled study of 161 cases of traumatic injury. Arthritis Rheum. 1997;40:446-52.
66. Zachariou V, Goldstein BD. Dynorphin(1-8) inhibits the release of substance P-like immunoreactivity in the spinal cord of rats following a noxious mechanical stimulus. Eur J Pharmacol. 1997;323:159-65.
67. Alarcon GS, Bradley LA, Hadley MN, Sotolongo A, Alberts KR, Martin MY, et al. Does Chiari formation contribute to fibromyalgia (FM) symptoms? Arthritis Rheum. 1997;40(suppl):S190.